Cancer antigens CA125 (multiple epitote) recognised by OC125, M11, B43.13, B27.1, where B43.13 is used as a binding agent to elicit host immune response as a vaccination method against cancer

摘要

A therapeutic composition comprising an effective amount of a binding agent specific for a first epitote on a multi-epitote in vivo antigen present in the host's serum which the antigen does not elicit a host immune response; wherein the binding agent present in the composition is exclusive of B43.13. The binding agent specifically binds to a first epitote on the antigen and forms a binding agent/antigen pair, whereby effective host immune response is elicited against a second epitote on the antigen.